Accufy Diagnostics discloses $2M equity raise in SEC filing
What's the deal? Accufy Diagnostics, a Rockville, Maryland biotech, has raised $2 million, selling the full offering to three investors, according to a Form D filing with the Securities and Exchange Commission. The filing lists a signature date of October 28, 2026, and a first sale on October 15.
The fine print: Accufy claimed a Rule 506(b) exemption under Regulation D and offered equity securities. The minimum investment from any outside investor was $300,000, and no sales commissions or finder's fees were reported.
What's the endgame? The Delaware-incorporated company, formed in 2023, is developing next-generation sequencing liquid biopsies for earlier cancer detection and measurable residual disease (MRD) monitoring.
Who's behind it? The filing names Jeffrey Hung and Zhixiong Xu as executive officers and directors. Hung signed the form as chief executive officer.
What to watch: The details come from a regulatory filing, not a company announcement, so investor names, valuation, and round terms are not public. The company declined to disclose its revenue or net asset value.
The signal: At this size, the raise is a modest step toward developing and validating the technology — not evidence of clinical or commercial traction. It lands in a crowded field, where larger players like Guardant Health continue to advance ctDNA-based MRD monitoring.
Read more: app.readthrough.bio
Image credit: Generated with Gemini
